Optimizing Rheumatology Prior Authorization with Experian Health Clearinghouse

Klivira optimizes rheumatology prior authorizations by integrating directly with your EMR and connecting seamlessly through the Experian Health Clearinghouse for efficient revenue cycle management.

Revenue cycle leaders and prior authorization coordinators in rheumatology face significant challenges managing high-volume, complex PAs for biologics and specialty drugs. Integrating an intelligent automation platform with your existing Experian Health Clearinghouse workflow is critical to accelerating approvals and minimizing administrative burden.

The Intersection of Rheumatology PA Complexity and Clearinghouse Efficiency

Rheumatology practices frequently manage prior authorizations for high-cost biologics and targeted synthetic DMARDs, including TNF-alpha inhibitors, non-TNF biologics, and JAK inhibitors. These require stringent documentation and often trigger step therapy protocols. Leveraging the Experian Health Clearinghouse for claims and eligibility, while automating PA submissions, creates a unified approach to revenue cycle management.

Key Rheumatology PA Triggers and Documentation Requirements

Biologics for RA, PsA, AS, SLE (e.g., Humira, Enbrel, Stelara, Skyrizi, Rinvoq) and infusion therapies.
Advanced imaging (MRI) and DEXA scans for inflammatory arthritis and osteoporosis management.
Diagnosis documentation per ACR/EULAR/CASPAR/ASAS criteria, including ICD-10 codes.
Disease activity assessments (DAS28, CDAI, SDAI, PASI, BASDAI, SLEDAI).
Documentation of prior conventional DMARD trials and step therapy compliance, often requiring specific biosimilar substitution.

Klivira's Role in Enhancing Experian Health Clearinghouse for Rheumatology

Klivira integrates directly with your EMR, pulling clinical data to intelligently pre-populate prior authorization requests. For rheumatology, this means automatically extracting disease activity scores, prior treatment history, and screening results. These structured data points are then routed to payers via the most efficient channel, including X12 278 electronic prior authorization (ePA) through the Experian Health Clearinghouse, or directly to payer portals.

Addressing Rheumatology-Specific PA Challenges

**Chronic Treatment Re-authorization:** Klivira automates periodic re-authorization workflows for ongoing biologic therapies, prompting for continuous disease response documentation.
**Biosimilar and Step Therapy Management:** Our ACR-guideline-aware policy logic handles payer-specific biosimilar substitution mandates and complex step therapy sequences.
**Medical vs. Pharmacy Benefit Split:** The platform intelligently routes PAs for agents that may fall under either medical or pharmacy benefits depending on administration mode and payer policy.
**Denial Prevention:** By ensuring comprehensive documentation for disease activity, prior trials, and screenings, Klivira reduces common denial reasons like 'step therapy not completed' or 'disease activity not documented'.

Seamless EMR Integration and Data Exchange

Klivira leverages SMART on FHIR for secure, bidirectional data exchange with leading EMRs, ensuring that clinical information required for rheumatology PAs is accurately captured. This integration facilitates the automated submission of requests through the Experian Health Clearinghouse, enhancing the efficiency of your revenue cycle operations and ensuring compliance with data security standards like HIPAA for ePHI.

Optimizing Prior Authorization Submission Channels

While Experian Health Clearinghouse excels at claims and eligibility, Klivira extends its capabilities to PA by intelligently choosing the optimal submission channel for each rheumatology case. This includes electronic submission via X12 278 ePA, direct integrations with payer portals, or, when necessary, managing fax and phone submissions, ensuring that even complex cases for specific biologics are processed efficiently.

Frequently asked questions

How does Klivira integrate with Experian Health Clearinghouse for rheumatology PAs?

Klivira integrates with your EMR to extract clinical data for rheumatology PAs. This data is then used to generate and submit PA requests electronically via X12 278 through the Experian Health Clearinghouse, streamlining the process and reducing manual intervention for both clinical and revenue cycle teams.

What specific rheumatology drugs benefit most from this integration?

This integration is particularly beneficial for high-cost biologics and targeted therapies, including TNF-alpha inhibitors (e.g., adalimumab, etanercept), non-TNF biologics (e.g., IL-6, IL-17, IL-23 inhibitors), and JAK inhibitors. These agents frequently require complex prior authorization with detailed clinical criteria and step therapy adherence.

How does this solution handle chronic re-authorizations for rheumatology patients?

Klivira's platform includes a dedicated workflow for periodic re-authorizations, common in chronic rheumatology conditions. It tracks approval expiry dates, prompts for necessary updated disease activity assessments (e.g., DAS28, CDAI), and automates the re-submission process, ensuring continuity of care and preventing treatment gaps due to lapsed PAs.

Can Klivira manage both medical and pharmacy benefit PAs through Experian Health?

Yes, Klivira's logic distinguishes between medical and pharmacy benefit prior authorizations. For rheumatology, where some biologics can be self-administered (pharmacy benefit) or provider-administered (medical benefit), the system routes the PA request appropriately, often leveraging the X12 278 channel for medical benefit PAs via the clearinghouse.

What are the typical EMR integration points for rheumatology practices?

Klivira integrates with EMRs via SMART on FHIR, connecting to modules for patient demographics, problem lists, medication history, lab results (e.g., inflammatory markers, TB/hepatitis screenings), and clinical notes. This allows for automated data extraction to fulfill documentation requirements like disease activity scores, prior DMARD trials, and diagnostic criteria.